Companies
/Healthcare
Vertex Pharmaceuticals Inc
$534.20
▼ $3.59 (−0.67%) today
Markets closed · 5:47pm ET
Vertex Pharmaceuticals (VRTX) Earnings History & Trends
57%
EPS beat rate
+1.02%
Avg. EPS surprise
Consecutive EPS beats
VRTX vs Market · 30-day return after each reportVRTXS&P 500
VRTX EPS Trend · estimate vs actualEstimateActual
VRTX Revenue Trend · estimate vs actualEstimateActual
How Often Does Vertex Pharmaceuticals Beat Earnings Estimates?
Vertex Pharmaceuticals beat EPS estimates in 4 of its last 7 reported quarters.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Non-GAAP EPS excludes $502.0 million of acquisition-related costs (primarily compensation for cash-settled unvested Crinetics equity awards and transaction costs), $174.4 million of stock-based compensation, $20.9 million of intangible amortization and $5.4 million of acquired inventory step-up; GAAP diluted EPS was $2.56. | $4.76 est. $4.75 | +0.17% | $3.4B est. $3.4B | +0.30% |
| Q2 2026 | $4.73 est. $4.75 | −0.32% | $3.3B est. $3.2B | +3.43% |
| Q1 2026 | $4.47 est. $4.31 | +3.81% | $3.0B est. $3.0B | −0.36% |
| Q4 2025 | $5.03 est. $5.15 | −2.30% | $3.2B est. $3.2B | +0.48% |
| Q3 2025 | $4.80 est. $4.58 | +4.87% | $3.1B est. $3.1B | +0.56% |
| Q2 2025 | $4.52 est. $4.25 | +6.33% | $3.0B est. $2.9B | +2.00% |
| Q1 2025 | $4.06 est. $4.29 | −5.44% | $2.8B est. $2.9B | −3.17% |
Figures from SEC filings and company reports. Not investment advice.